NYSE : TEVA
Teva Pharmaceutical Industries Limited — Key statistics
Healthcare · Drug Manufacturers - Specialty & Generic · Israel
Last price 41.47 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 48.32B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 49.05B |
| Enterprise Value | 62.29B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 1.17B |
| Shares Outstanding | 1.17B |
| Shares Change (YoY) | +2.24% |
| Shares Change (QoQ) | -1.19% |
| Owned by Insiders (%) | 0.43% |
| Owned by Institutions (%) | 73.09% |
| Float | 1.09B |
Ratios
| Measure | Value |
|---|
| PE Ratio | 69.95 |
| Forward PE | 14.89 |
| PS Ratio | 2.83 |
| Forward PS | 2.92 |
| PB Ratio | 6.33 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 36.41 |
| P/OCF Ratio | 25.84 |
| PEG Ratio | 2.04 |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 88.22 |
| EV / Sales | 3.60 |
| EV / EBITDA | 14.59 |
| EV / EBIT | 18.99 |
| EV / FCF | 46.24 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.88 |
| Quick Ratio | 0.46 |
| Debt / Equity | 2.18 |
| Debt / EBITDA | 3.84 |
| Debt / FCF | 12.54 |
| Interest Coverage | 3.81 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 9.69% |
| Return on Assets (ROA) | 5.13% |
| Return on Invested Capital (ROIC) | 15.21% |
| Return on Capital Employed (ROCE) | 13.55% |
| Weighted Average Cost of Capital (WACC) | 7.79% |
| Revenue Per Employee | $510,015 |
| Profits Per Employee | $20,795 |
| Employee Count | 33,950 |
| Asset Turnover | 0.43 |
| Inventory Turnover | 2.45 |
Taxes
| Measure | Value |
|---|
| Income Tax | 12.00M |
| Effective Tax Rate | 1.67% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.82 |
| 52-Week Price Change | +108.06% |
| 50-Day Moving Average | 39.09 |
| 200-Day Moving Average | 34.58 |
| Relative Strength Index (RSI) | 63.68 |
| Average Volume (20 Days) | 6,178,289 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 28.07M |
| Short Previous Month | 31.48M |
| Short % of Shares Out | 2.42% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 4.40 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 17.32B |
| Gross Profit | 9.08B |
| Operating Income | 3.28B |
| Pretax Income | 719.00M |
| Net Income | 706.00M |
| EBITDA | 4.27B |
| EBIT | 3.28B |
| Earnings Per Share (EPS) | $0.60 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 3.66B |
| Total Debt | 16.89B |
| Net Cash | -13.24B |
| Net Cash Per Share | -$11.36 |
| Equity (Book Value) | 7.76B |
| Book Value Per Share | 6.65 |
| Working Capital | -1.89B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 1.90B |
| Capital Expenditures | -551.00M |
| Depreciation & Amortization | 988.00M |
| Net Borrowing | -474.00M |
| Free Cash Flow | 1.35B |
| FCF Per Share | $1.16 |
Margins
| Measure | Value |
|---|
| Gross Margin | 52.46% |
| Operating Margin | 18.94% |
| Pretax Margin | 4.15% |
| Profit Margin | 4.08% |
| EBITDA Margin | 24.65% |
| EBIT Margin | 18.94% |
| FCF Margin | 7.78% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -2.24% |
| Shareholder Yield | -2.24% |
| Earnings Yield | 1.43% |
| FCF Yield | 2.75% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $47.58 |
| Price Target Difference | 13.04% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (3Y) | 1.34% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 0.68 |
| Piotroski F-Score | 7 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |